바이오마커 제휴 및 라이선싱 계약(2016-2026년)

The definitive benchmark for biomarker dealmaking

Biomarker partnering is driven by data, discovery, and precision medicine strategies, with deal structures reflecting the role of biomarkers in target identification, patient stratification, and clinical development.

This report provides a comprehensive and structured analysis of 590+ biomarker collaboration and licensing deals, delivering a clear and evidence-based view of how partnerships are designed, negotiated, and executed across the market.

Establish a clear view of market standards

The report enables a precise understanding of how biomarker deals are structured in practice, allowing you to:

• Benchmark comparable transactions with confidence
• Detailed analysis of upfronts, milestones, and royalty structures across relevant deals
• Define realistic market parameters
• Clear insight into how deal terms vary by application, data type, and partner profile
• Support valuation and structuring decisions with evidence
• Ground internal discussions in real transaction data rather than assumptions
• Understand how leading companies approach dealmaking
• Visibility into partner behaviour and recurring deal structures across a data-driven and research-intensive landscape
• Full visibility into deal structure and execution
• Beyond headline deal data, the report provides access to underlying contract documents, enabling a detailed understanding of how agreements are constructed in practice.

This includes:

• Rights granted and retained
• Development and commercialization responsibilities
• Financial structures and payment triggers
• Key contractual provisions and protections
• This level of transparency is critical to understanding how value, risk, and control are allocated within biomarker partnerships, particularly in early-stage discovery and development contexts.
• Designed for real-world BD and strategy use

The report is widely used to:

• Structure and benchmark biomarker and discovery-driven transactions
• Prepare for negotiations with well-defined market context
• Evaluate data, platform, and collaboration opportunities
• Support internal strategy with robust, defensible data
• What's included
• 590+ biomarker collaboration and licensing deals
• Financial terms, including upfronts, milestones, and royalties where disclosed
• Fully searchable deal directory (by company, application, and data type)
• Direct access to SEC-filed agreements and source documents
• Analysis of deal trends, key transactions, and active dealmakers
• A trusted, evidence-based reference for biomarker dealmaking
• Combining comprehensive deal coverage with contract-level insight, this report provides a trusted, evidence-based reference for how biomarker partnerships are structured, negotiated, and valued.

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in biomarker dealmaking

• 2.1. Introduction
• 2.2. Biomarker deals over the years
• 2.3. Most active biomarker dealmakers
• 2.4. Biomarker deals by deal type
• 2.5. Biomarker deals by therapy area
• 2.6. Biomarker deals by industry sector
• 2.7. Deal terms for biomarker deals
  • 2.7.1 Biomarker deals headline values
  • 2.7.2 Biomarker deal upfront payments
  • 2.7.3 Biomarker deal milestone payments
  • 2.7.4 Biomarker royalty rates

Chapter 3 - Leading biomarker deals

• 3.1. Introduction
• 3.2. Top biomarker deals by value

Chapter 4 - Most active biomarker dealmakers

• 4.1. Introduction
• 4.2. Most active biomarker dealmakers
• 4.3. Most active biomarker deals company profiles

Chapter 5 - Biomarker contracts dealmaking directory

• 5.1. Introduction
• 5.2. Biomarker contracts dealmaking directory

Chapter 6 - Biomarker dealmaking by technology type

• Deal directory
• Deal directory - Biomarker deals by company A-Z
• Deal directory - Biomarker deals by deal type
• Deal directory - Biomarker deals by therapy area
• Deal type definitions
• About Biopharma Research Ltd
• Current Partnering
• Current Agreements
• Recent report titles from Current Partnering

Table of figures

• Figure 1: Biomarker deals since 2016
• Figure 2: Active biomarker dealmaking activity since 2016
• Figure 3: Biomarker deals by deal type since 2016
• Figure 4: Biomarker deals by therapy area since 2016
• Figure 5: Biomarker deals by industry sector since 2016
• Figure 6: Biomarker deals with a headline value
• Figure 7: Biomarker deals with an upfront value
• Figure 8: Biomarker deals with a milestone value
• Figure 9: Biomarker deals with a royalty rate value
• Figure 10: Top biomarker deals by value since 2016
• Figure 11: Most active biomarker dealmakers since 2016
• Figure 12: Biomarker deals by technology type since 2016